☆ 4.3 Article

Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy

Koki Obayashi et al.

Summary: The study evaluates the potential of Lung Immune Prognostic Index (LIPI) as a preoperative biomarker for patients with bladder cancer, showing LIPI can predict the prognosis of patients undergoing radical cystectomy and has better predictive ability when combined with pT3/4 and lymph node metastasis.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB

Jia Chen et al.

Summary: This study assessed the prognostic value of pretreatment serum biomarkers in stage IV non-small-cell lung cancer patients treated with PD-1 inhibitors and found that pretreatment dNLR is an independent prognostic indicator of both PFS and OS. Additionally, pretreatment LIPI score, when combined with specific markers, can also predict patient outcomes.

DISEASE MARKERS (2022)

添加到收藏夹

Article Oncology

Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma

Yu Miyama et al.

Summary: The study found that younger age, lower NLR, and positive PD-L1 expression were significantly associated with longer survival in UC patients treated with pembrolizumab. These results suggest that both host and tumor status can reflect the effectiveness of pembrolizumab in UC patients.

CANCER MEDICINE (2022)

添加到收藏夹

Review Oncology

Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review

Yusheng Guo et al.

Summary: This meta-analysis and systematic review study summarized the dynamics of neutrophil-to-lymphocyte ratio (NLR) after immune checkpoint inhibitor (ICI) treatment and its association with clinical outcomes. The results showed that patients without response to immunotherapy may experience an increase in NLR after ICI treatment, and an upward trend in NLR was associated with worse clinical outcomes, while a downward trend in NLR was associated with better clinical outcomes. Post-treatment high NLR was more strongly associated with impaired survival than baseline high NLR.

CANCERS (2022)

添加到收藏夹

Review Urology & Nephrology

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

J. Alfred Witjes et al.

Summary: This article presents the updated European Association of Urology guidelines for muscle-invasive and metastatic bladder cancer, providing practical evidence-based recommendations and consensus statements on clinical management. The guidelines cover a broad scope and incorporate the latest research findings and results from consensus meetings.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy

Yudai Ishiyama et al.

Summary: The study revealed that PNI is a prognostic indicator for metastatic urothelial carcinoma patients receiving pembrolizumab, with patients in the low PNI group showing shorter progression-free survival and overall survival.

ANTICANCER RESEARCH (2021)

添加到收藏夹

Review Oncology

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Xiuqiong Chen et al.

Summary: Elevated NLR is associated with adverse OS and PFS in patients with RCC treated with ICIs. Age, sex, race, and IMDC risk may have potential predictive value for the prognosis of RCC treated with ICIs. Further investigations are warranted to validate these results.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy A meta-analysis

Jun Xu et al.

Summary: This meta-analysis suggests that a higher pretreatment LDH level is significantly associated with worse overall survival and shorter progression-free survival in melanoma patients receiving anti-PD1/PD-L1 monotherapy.

MEDICINE (2021)

添加到收藏夹

Review Oncology

Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review

Ekaterina Laukhtina et al.

Summary: The systematic review aimed to identify prognostic values of blood-based biomarkers in UCB patients treated with NAC, revealing associations between certain markers and tumor pathologic response, survival outcomes, and the potential to improve patient selection for NAC.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2021)

添加到收藏夹

Review Oncology

The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis

Hui Liu et al.

Summary: The study found that a good LIPI score was significantly associated with improved overall survival (OS) and progression-free survival (PFS) in cancer patients receiving ICIs or chemotherapy, while a poor LIPI score was linked to worse treatment outcomes.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis

Tao Yang et al.

Summary: This study evaluated the association between pretreatment dNLR and prognosis of patients with NSCLC treated with ICIs through systematic review and meta-analysis. The results showed that higher dNLR levels significantly predicted poor overall survival and progression-free survival in NSCLC patients.

BMJ OPEN (2021)

添加到收藏夹

Review Oncology

Lactate dehydrogenase: a marker of diminished antitumor immunity

Sandra Van Wilpe et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Review Immunology

C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights

Peter C. Hart et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Y. Fradet et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials

Michael J. Sorich et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis

Dongbo Liu et al.

CANCER MANAGEMENT AND RESEARCH (2019)

添加到收藏夹

Article Oncology

Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma

Hiroki Ishihara et al.

TARGETED ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer

Dickran Kazandjian et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

Daniel E. Meyers et al.

CANCERS (2019)

添加到收藏夹

Article Oncology

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

Danielle Benedict Sacdalan et al.

ONCOTARGETS AND THERAPY (2018)

添加到收藏夹

Article Oncology

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Laura Mezquita et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Mariaelena Capone et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Biology

Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab

Hisako Okuhira et al.

BIOSCIENCE TRENDS (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Prognostic Value of Lactate Dehydrogenase in Patients with Hepatocellular Carcinoma: A Meta-Analysis

Weihao Kong et al.

BIOMED RESEARCH INTERNATIONAL (2018)

添加到收藏夹

Article Urology & Nephrology

Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions

Abhishek Tripathi et al.

CURRENT UROLOGY REPORTS (2018)

添加到收藏夹

Article Oncology

The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study

Jeenan Kaiser et al.

BLADDER CANCER (2018)

添加到收藏夹

Correction Oncology

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab (vol 27, pg 732, 2016)

P. F. Ferrucci et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Markus V. Heppt et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Stefan Diem et al.

LUNG CANCER (2017)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

J. Bellmunt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer

Oscar Buisan et al.

CLINICAL GENITOURINARY CANCER (2017)

添加到收藏夹

Article Oncology

Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients

Yuanyuan Xiao et al.

BMC CANCER (2017)

添加到收藏夹

Article Oncology

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

S. Diem et al.

BRITISH JOURNAL OF CANCER (2016)

添加到收藏夹

Article Oncology

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Benjamin Weide et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Oncology

Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies

Fausto Petrelli et al.

ACTA ONCOLOGICA (2015)

添加到收藏夹

Review Oncology

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Arnoud J. Templeton et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.